Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation

Jessica K. Altman, MD, Selina M. Luger, MD FRCPC, Olga Frankfurt, MD, Tsila Zuckerman, MD, Jamie L. Koprivnikar, MD, Vamsi Kota, MD, Ashkan Emadi, MD, PhD, Bhavana Bhatnagar, DO, Dale L. Bixby, MD, Micah M. Burch, MD, Ofir Wolach, MD, Itai Levi, MD, Anna Gourevitch, MD, Ron Ram, MD, Liat Flaishon, PhD MD, Shoshi Tessler, PhD, Stela Gengrinovitch, PhD, Ruth Ben Yakar, PhD, Jacob M. Rowe, MB, BS

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-139136

Published: 2020

Journal Articles

Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study

Robert Zeiser, PhD, Nicola Polverelli, MD PhD, Ron Ram, MD, Shahrukh K. Hashmi, MDMPH, Ronjon Chakraverty, BMBS, PhD, Mary E. D. Flowers, MD, Fitzroy Dawkins, MD, Norbert Hollaender, MD, Maanasa Gowda, PharmD, Tommaso Stefanelli, MD, Stephanie J. Lee, MDMPH, Takanori Teshima, MD, Franco Locatelli, MD PhD

Blood (2020) 136 (Supplement 1): 22–24.

https://doi.org/10.1182/blood-2020-137694

Published: 2020

Journal Articles

Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integrated Results from a Phase 1/2a and an Ongoing Phase 2b

Jessica K. Altman, Tsila Zuckerman, MD, Olga Frankfurt, MD, Selina M. Luger, MD FRCPC, Dale L. Bixby, MD, Vamsi Kota, MBBS, Micah M. Burch, Ofir Wolach, Itai Levi, MD, Anna Gourevitch, Ron Ram, MD, Liat Flaishon, Shoshi Tessler, Stela Gengrinovitch, Ruth Ben Yakar, Jacob M. Rowe, MB, BS

Blood (2019) 134 (Supplement_1): 179.

https://doi.org/10.1182/blood-2019-124330

Published: 2019

Journal Articles

Is the Achievement of Pre-Autologous Transplant CR Necessary Indeed in Refractory/ Relapsed DLBCL Patients? a Retrospective Multicenter Study

Liat Shargian-Alon, MD, Hanna Bernstine, Galit Perets, MD, Ronit Gurion, Anat Gafter-Gvili, MD, Oren Pasvolsky, MD, Michal Navon Sela, Chava Perry, MD PhD, Irit Avivi, MD, Odelia Amit, MD, Pia Raanani, MD, Ron Ram, MD, Moshe Yeshurun, MD

Blood (2019) 134 (Supplement_1): 5703.

https://doi.org/10.1182/blood-2019-131229

Published: 2019

Journal Articles

Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML

Chezi Ganzel, MD, Ron Ram, MD, Alexander Gural, MD, Ofir Wolach, MD, Sharon Gino-Moor, MD, Vladimir Vainstein, MD, Boaz Nachmias, MD PhD, Arie Apel, MD, Maya Koren-Michowitz, MD, Oren Pasvolsky, MD, Ronit Yerushalmi, MD, Ivetta Danylesko, Yoseph Cohen, MD, Galit Perets, Yakir Moshe, MD, Miri Zektzer, MD, Shay Yeganeh, MD, Jacob M. Rowe, MB, BS, Yishai Ofran, MD

Blood (2019) 134 (Supplement_1): 5091.

https://doi.org/10.1182/blood-2019-125662

Published: 2019

Journal Articles

Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Yafit Segman, MD, Elena Ribakovsky, MD, Abraham Avigdor, MD, Vladimir Vainstein, MD, Neta Goldschmidt, MD, Shimrit Ringelstein Harlev, MD, Odit Gutwein, Uri Abadi, MD, Anatoly Nemets, MD, Orit Sofer, Najib Dally, MD, Kalman Filanovsky, MD, Merav Leiba, MD, Nadav Sarid, MD, Noam Benyamini, MD, Yair Herishanu, MD, Ron Ram, MD, Chava Perry, MD PhD, Irit Avivi

Blood (2019) 134 (Supplement_1): 5321.

https://doi.org/10.1182/blood-2019-124164

Published: 2019

Journal Articles

Venetoclax and DLI for Patients with Early Relapse of Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. a Historical Prospective Multicenter Trial

Odelia Amit, MD, Yael Bar-On, MD, Galit Perets, MD, Lena Atlas, Liat Shargian, MD, Moshe Yeshurun, MD, Bruria Yachini, RN, Chen Karni, RN, Ron Ram, MD

Blood (2019) 134 (Supplement_1): 2018.

https://doi.org/10.1182/blood-2019-126999

Published: 2019

Journal Articles

Radiation-Free Protocol for Patients with Acute Lymphoblastic Leukemia and Mixed Phenotype Acute Leukemia Undergoing Induction Chemotherapy and Allogeneic Hematopoietic Cell Transplantation - a Multicenter Historical Prospective Study

Odelia Amit, MD, Yael Bar-On, MD, Irit Avivi, Tsila Zuckerman, MD, Galit Perets, MD, Israel Henig, MD, Itai Levi, MD, Dana Yehudai-Ofir, MD, Shimrit Ringelstein Harlev, MD, Ron Ram, MD

Blood (2019) 134 (Supplement_1): 5654.

https://doi.org/10.1182/blood-2019-128248

Published: 2019

Journal Articles

Adding Midostaurin to Intensive Chemotherapy in FLT3-Positive AML Patients. Results from a Multicenter Historical-Controlled Study

Tamar Berger, MD, Yakir Moshe, MD, Shilo Yaari, Ilana Hellmann, MD, Adina Aviram, PhD, Pia Raanani, Ron Ram, MD, Yishai Ofran, MD, Ofir Wolach, MD

Blood (2018) 132 (Supplement 1): 4005.

https://doi.org/10.1182/blood-2018-99-114154

Published: 2018

Journal Articles

Safety and Efficacy of Blinatumomab- Real World Data

Arie Apel, MD, Yishai Ofran, MD, Ron Ram, MD, Itai Levi, MD, Miri Zektser, MD, Maya Koren-Michowitz, MD

Blood (2018) 132 (Supplement 1): 5209.

https://doi.org/10.1182/blood-2018-99-116183

Published: 2018

Journal Articles

Addition of Venetoclax to Patients with Acute Myeloid Leukemia Relapsing after Treatment with Hypomethylating Agents. Multicenter Historical Prospective Study

Ron Ram, MD, Odelia Amit, MD, Tsila Zuckerman, MD, Ronit Gurion, Pia Raanani, Yael Bar-On, MD, Irit Avivi, MD, Ofir Wolach, MD

Blood (2018) 132 (Supplement 1): 4046.

https://doi.org/10.1182/blood-2018-99-113596

Published: 2018

Journal Articles

Eltrombopag for Enhancement of Platelet Engraftment in Patients Undergoing Allogeneic Cord Blood Transplantation

Oren Pasvolsky, Liat Shargian, MD, Uri Rozovski, Ron Ram, MD, Michael Y. Shapira, MD, Moshe Israeli, Liat Vidal-Fisher, MD MSc, Ofer Shpilberg, MD MPH, Pia Raanani, Moshe Yeshurun

Blood (2018) 132 (Supplement 1): 2092.

https://doi.org/10.1182/blood-2018-99-116048

Published: 2018

Journal Articles

Low Risk for Viral Reactivation during Induction for Acute Myeloid Leukemia in Hepatitis B Silent Carriers Who Are Negativefor Hepatitis B Surface Antigen

Tsofia Inbar, MD, Shehrban Sobeh Khalil, MD, Ron Ram, MD, Chezi Ganzel, MD, Yishai Ofran, MD

Blood (2017) 130 (Supplement 1): 2172.

https://doi.org/10.1182/blood.V130.Suppl_1.2172.2172

Published: 2017

Journal Articles

Sequential Therapy for Patients with Primary Refractory AML — a Retrospective Analysis of the German and Israeli Experience

Ron Ram, MD, Christof Scheid, MD, Odelia Amit, BSc, Jens Markus Chemnitz ‎, MD, Yakir Moshe, MD, Michael Hallek, MD, Dominik Wolf‎, Irit Avivi, MD, Udo Holtick, MD PhD

Blood (2017) 130 (Supplement 1): 4579.

https://doi.org/10.1182/blood.V130.Suppl_1.4579.4579

Published: 2017

Journal Articles

BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study

Tsila Zuckerman, MD, Ron Ram, MD, Maya Koren-Michowitz, MD, Luiza Akria, MD, Ron Hoffman, Israel Henig, MD, Yishai Ofran, MD, Noa Lavi, MD, Netanel A Horowitz, MD, Olga Nudelman, MD, Shay Yeganeh, MD, Stela Gengrinovitch, PhD, Liat Flaishon, PhD MD, Ruth Ben Yakar, PhD, Jacob M. Rowe, MD

Blood (2017) 130 (Supplement 1): 893.

https://doi.org/10.1182/blood.V130.Suppl_1.893.893

Published: 2017

Journal Articles

Bolus Versus Prolonged Infusion of Broad-Spectrum Beta-Lactams for Patients with Hematologic Malignancies and High Risk Febrile Neutropenia - a Single Center Prospective Unblinded Randomized Trial

Ron Ram, MD, Irit Avivi, MD, Odelia Amit, BSc, Yael Halavy, Yael Paran, MD, Eugene Katchman, Bruria Yachini, RN, Kor Svetlana, RN, Ronen Ben Ami, MD

Blood (2017) 130 (Supplement 1): 282.

https://doi.org/10.1182/blood.V130.Suppl_1.282.282

Published: 2017

Journal Articles

Real-Life Experience with Ponatinib in Chronic Myeloid Leukemia (CML): A Multicenter Observational Study

Adi Shacham Abulafia, Pia Raanani, David Lavie, Yulia Volchek, Ron Ram, MD, Ilana Hellman, Liat Shargian, Anna Gourevietch, Evgeni Chubar, MD, Roy Ratzon, MD, Uri Rozovski

Blood (2017) 130 (Supplement 1): 5249.

https://doi.org/10.1182/blood.V130.Suppl_1.5249.5249

Published: 2017

Journal Articles

Beac and BEAM High-Dose Chemotherapy in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation Are Efficacious, with Comparable Toxicity

Noa Lavi, MD, Ron Ram, MD, Odelia Amit, MD, Netanel A Horowitz, MD, Tzila Zuckerman, MD

Blood (2016) 128 (22): 5828.

https://doi.org/10.1182/blood.V128.22.5828.5828

Published: 2016

Journal Articles

Treatment Patterns and Clinical Outcomes in High-Risk Multiple Myeloma Patients Carrying the 17p Deletion: A Multi-Center Retrospective Observational Study

Yael Cohen, MD, Moshe E. Gatt, MD, Noa Lavi, MD, Chezi Ganzel, Hila Magen, MD, Irit Avivi, MD, Tamar Tadmor, MD, Celia Suriu, MD, Osnat Jarchowsky Dolberg, Amitai Papushado, MD, Svetlana Trestman, MD, Ron Ram, MD

Blood (2016) 128 (22): 4510.

https://doi.org/10.1182/blood.V128.22.4510.4510

Published: 2016

Journal Articles

A Nationwide Observational Study of the Israeli Experience with Ponatinib Outside Clinical Trials in Chronic Myeloid Leukemia

Adi Shacham Abulafia, MD, Pia Raanani, MD, David Lavie, MD, Yulia Volchek, MD, Ron Ram, MD, Ilana Hellmann, MD, Liat Shargian, MD, Anna Gourevietch, MD, Evgeni Chubar, MD, Roy Ratzon, BSC, Uri Rozovski, MD

Blood (2015) 126 (23): 5155.

https://doi.org/10.1182/blood.V126.23.5155.5155

Published: 2015

NARROW

Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation

Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study

Aspacytarabine (BST-236) Is Safe and Efficacious As a Single-Agent, First-Line Therapy for Patients with Acute Myeloid Leukemia Unfit for Standard Chemotherapy. Integrated Results from a Phase 1/2a and an Ongoing Phase 2b

Is the Achievement of Pre-Autologous Transplant CR Necessary Indeed in Refractory/ Relapsed DLBCL Patients? a Retrospective Multicenter Study

Venetoclax Is Safe and Efficacious in Relapsed/ Refractory AML

Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Venetoclax and DLI for Patients with Early Relapse of Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. a Historical Prospective Multicenter Trial

Radiation-Free Protocol for Patients with Acute Lymphoblastic Leukemia and Mixed Phenotype Acute Leukemia Undergoing Induction Chemotherapy and Allogeneic Hematopoietic Cell Transplantation - a Multicenter Historical Prospective Study

Adding Midostaurin to Intensive Chemotherapy in FLT3-Positive AML Patients. Results from a Multicenter Historical-Controlled Study

Safety and Efficacy of Blinatumomab- Real World Data

Addition of Venetoclax to Patients with Acute Myeloid Leukemia Relapsing after Treatment with Hypomethylating Agents. Multicenter Historical Prospective Study

Eltrombopag for Enhancement of Platelet Engraftment in Patients Undergoing Allogeneic Cord Blood Transplantation

Low Risk for Viral Reactivation during Induction for Acute Myeloid Leukemia in Hepatitis B Silent Carriers Who Are Negativefor Hepatitis B Surface Antigen

Sequential Therapy for Patients with Primary Refractory AML — a Retrospective Analysis of the German and Israeli Experience

BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study

Bolus Versus Prolonged Infusion of Broad-Spectrum Beta-Lactams for Patients with Hematologic Malignancies and High Risk Febrile Neutropenia - a Single Center Prospective Unblinded Randomized Trial

Real-Life Experience with Ponatinib in Chronic Myeloid Leukemia (CML): A Multicenter Observational Study

Beac and BEAM High-Dose Chemotherapy in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation Are Efficacious, with Comparable Toxicity

Treatment Patterns and Clinical Outcomes in High-Risk Multiple Myeloma Patients Carrying the 17p Deletion: A Multi-Center Retrospective Observational Study

A Nationwide Observational Study of the Israeli Experience with Ponatinib Outside Clinical Trials in Chronic Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only